A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an increased risk for nonarteritic anterior ischemic optic neuropathy.
The use of semaglutide, a glucagon-like peptide 1 receptor agonist , is not associated with an increased risk for nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes, obesity, or both conditions.Researchers conducted a retrospective cohort study using data from the TriNetX Analytics Network to investigate the potential risk for NAION associated with semaglutide use in a broader population worldwide.
The participants were further grouped into those prescribed semaglutide and those using non–GLP-1 RA medications. The use of semaglutide vs non–GLP-1 RAs was not associated with an increased risk for NAION in people with only type 2 diabetes during the 1-year , 2-year , and 3-year follow-up periods. The patients with both diabetes and obesity also showed no significant association between use of semaglutide and the risk for NAION across each follow-up period.
Non-Arteritic Anterior Ischemic Optic Neuropathy NAION - Nonarteritic Anterior Ischaemic Optic Neu Nonarteritic Anterior Ischaemic Optic Neuropathy Anterior Ischemic Optic Neuropathy AION - Anterior Ischemic Optic Neuropathy Aion - Anterior Ischemic Optic Neuropathy Optic Neuropathy Neuropathy Obesity Obese Diabetes Mellitus Type 2
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
More Evidence Ties Semaglutide to Reduced Alzheimer’s RiskThe GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Hormonal IUDs increase risk of breast cancer nearly the same as hormonal pills, study findsResearchers studied nearly 80,000 women ages 15 to 49 for the findings.
Read more »